Allergan Chops 1,500 Jobs to Fend Off Valeant
Allergan reported better-than-expected second-quarter 2014 results before markets opened Monday morning. The Botox-maker also announced that it will execute a restructuring in the second half of 2014.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 286Valeant Offer Weaker After Allergan Earnings
In a sharply worded press release Monday morning, Valeant Pharmaceuticals said that it "can no longer tolerate" statements from Allergan that are "attempts to mislead investors."
Deutsche Bank Raises Price Targets on Top Biotech and Health Care Stocks
New research reports from the biotech, health care and medical device teams at Deutsche Bank raise price targets on three top names to buy and include updates on two others.
Top Biotech Earnings Previews for the Week Ahead
ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will change during the week…
Analyst Issues Top Biotech Stocks to Buy Ahead of Earnings
ThinkstockFor the third time in less than two weeks, one of the top brokerage firms we cover at 24/7 Wall Street has loudly stepped up to the plate and advised investors to buy the top…
4 Key Positive Biotech Stock Catalysts Coming Very Soon
ThinkstockInvestors and speculators often flock to the world biotech for emerging drugs of the future. It is no secret at all that the biotech sector is full of all sorts of risks, making and…
4 Top Biotechs Expected to Beat Earnings Expectations
In a research note, Leerink analysts mentioned four specific top biotech names that may have the ability to beat current earnings expectations. But 24/7 Wall St. has one caveat.
Why the Exelixis Cancer Trial News Matters This Time
ThinkstockCancer treatment developer Exelixis Inc. (NASDAQ: EXEL) is trading very heavy volume today and getting a sharp price boost following a positive result in a phase 3 pivotal trial of a combination of drugs…
Abbott, Mylan Join Forces to Dodge U.S. Taxes
Add one more to the litany of pharmaceutical company mergers that are being made to avoid U.S. taxes. Mylan's existing business with part of Abbott's generic drug business.
UBS Very Bullish on Biotech Stocks Ahead of Second-Quarter Earnings
In a new research report, UBS analysts are very positive on some top biotech stocks before second-quarter earnings numbers hit the tape.
Breakthrough Blood Test in Identifying Alzheimer’s Disease
ThinkstockSometimes there are company reports from non-U.S. companies that are just too important to pass up. That was the case for Proteome Sciences PLC out of the United Kingdom on Tuesday. The company has…
Upcoming Catalysts Could Drive Seven Biotech and Health Care Stocks Higher
ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our 24/7 Wall Street research…
Washington State Issues First Retail Marijuana Licenses
ThinkstockWashington state issued its first retail marijuana licenses on Monday. The state’s Liquor Control Board notified two dozen stores so they could prepare before they are allowed to open their doors at 8 a.m.…
MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015
24/7 Wall St. ran a poll for investors this week on where MannKind shares would go into 2015, and the results were overwhelmingly bullish.
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
A new report from the analysts at Cowen shows that, on average, biotech stocks gained 84% in the 12 months prior to an FDA approval and lost 24% in the 12 months after the…